Eli Lilly is adding to an already prolific streak of biotechnology company acquisitions this year, purchasing on Monday a stealthy startup working on medicines for rare blood cancers.
Lilly is paying up to $1.5 billion to buy Calytrix Bio, a Wellesley, Massachusetts-based biotech working on treatments for slow-growing malignancies known as myeloproliferative neoplasms. Calytrix didn’t disclose how much guaranteed cash is involved in the deal, only noting that the offer includes an upfront payment and subsequent payouts tied to certain unspecified clinical and regulatory milestones.
Calytrix is developing treatments for myelofibrosis and essential thrombocythemia. Both conditions are forms of myeloproliferative neoplasms, which occur when the body overproduces red blood cells, leading to bone marrow scarring, clots and other health problems. These diseases can be treated with blood transfusions or “JAK” inhibitor drugs like Incyte’s Jakafi. Calytrix claims these therapies only manage symptoms and complications, though, leaving an opportunity for drugs that can precisely target disease-causing mutations.
Calytrix has invented a special type of double-barreled antibody it believes to be capable of changing disease trajectory for people whose disease is driven by mutations to a gene called “CALR.” When this mutation occurs, a particular cell-surface protein emerges that can be precisely targeted while sparing healthy tissue. Calytrix is doing so with a “biparatopic” antibody, a drug that binds to two separate sites on the same protein. It didn’t provide additional details on the therapy or its targets.
“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, Calytrix’s president and CEO, in a statement. “We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum.”
The purchase adds to a considerable streak for Lilly, which in an active year for biotech acquisitions has been the biotech sector’s most prolific dealmaker. Including Monday’s purchase, Lilly has spent more than $30 billion this year on 15 company acquisitions, the majority of which were privately held startups. The next-highest totals belong to GSK, Gilead Sciences and Novartis, all of which have bought three drug companies in 2026.
Calytrix was formed last year by a life sciences venture capital arm of J.P. Morgan Asset Management. Westlake BioPartners and Avoro Ventures backed the startup as well.